RTW Investments, LP

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

Retrieved on: 
Thursday, March 18, 2021
Biotechnology, Pharmaceutical, Health, Oncology, UroGen Pharma Ltd., RTW Investments, LP

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (RTW).

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (RTW).
  • The future payments on both Jelmyto and UGN-102 will terminate following the date that RTW has received an aggregate amount pursuant to such payments of $300 million.
  • We are proud to partner with the UroGen management team and look forward to supporting the Companys goal of building a leading uro-oncology company.
  • RTW Investments, LP (RTW) is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations in biopharmaceutical and medical technologies.

RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics Enter Intro Strategic Financing Collaboration to Support the Development of CK-274 and Enter China

Retrieved on: 
Wednesday, July 15, 2020
Health, Medical devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Cytokinetics, Royalty payment, XING, Social information processing, Health, Medical devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Cytokinetics, Royalty payment, XING, Social information processing, RTW Investments, LP, Ji Xing Pharmaceuticals

Ji Xing has committed to making an upfront payment plus $200 million in development and commercial milestones.

Key Points: 
  • Ji Xing has committed to making an upfront payment plus $200 million in development and commercial milestones.
  • As part of the agreement, Ji Xing will pay to Cytokinetics royalties on the net sales of the product in the region.
  • Affiliates of RTW have simultaneously entered into a broad strategic funding agreement and equity purchase agreement with Cytokinetics.
  • RTW is also proud to be unique in its ability to provide a mix of equity, non-dilutive capital, and geographic partnership to assist Cytokinetics in reaching its strategic goals.